Emergency Support for Substance Use Disorders Act

Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; H.R. 4341 and S. 987 - CARA 3.0 Act of 2021 - entire bill reauthorizing and expanding treatment and recovery for substance abuse disorders, including Medicare coverage and state programs; H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 - authorizes grants to entities for opioid response and requires prescriptions of opioid overdose reversal drugs when prescribing opioids; H.R. 4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to chemical and biological defense and access to Naloxone; H.R. 2471 - Consolidated Appropriations Act, 2022 - Division H - Department of Labor, Health and Human Services, and Education, and related agencies, appropriations Act, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government, substance abuse treatments and State Opioid Response Grants.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; H.R. 4341 and S. 987 - CARA 3.0 Act of 2021 - entire bill reauthorizing and expanding treatment and recovery for substance abuse disorders, including Medicare coverage and state programs; H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 - authorizes grants to entities for opioid response and requires prescriptions of opioid overdose reversal drugs when prescribing opioids; H.R. 4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to chemical and biological defense and access to Naloxone; H.R. 2471 - Consolidated Appropriations Act, 2022 - Division H - Department of Labor, Health and Human Services, and Education, and related agencies, appropriations Act, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government, substance abuse treatments and State Opioid Response Grants.

Client expense: Not reported · Firm income: $20,000

Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; H.R. 4341 and S. 987 - CARA 3.0 Act of 2021 - entire bill reauthorizing and expanding treatment and recovery for substance abuse disorders, including Medicare coverage and state programs; H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 - authorizes grants to entities for opioid response and requires prescriptions of opioid overdose reversal drugs when prescribing opioids; H.R. 4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to chemical and biological defense and access to Naloxone; H.R. 2471 - Consolidated Appropriations Act, 2022 - Division H - Department of Labor, Health and Human Services, and Education, and related agencies, appropriations Act, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government, substance abuse treatments and State Opioid Response Grants.

Client expense: Not reported · Firm income: $20,000

Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; H.R. 4341 and S. 987 - CARA 3.0 Act of 2021 - entire bill reauthorizing and expanding treatment and recovery for substance abuse disorders, including Medicare coverage and state programs; H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 - authorizes grants to entities for opioid response and requires prescriptions of opioid overdose reversal drugs when prescribing opioids; H.R. 4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to chemical and biological defense and access to Naloxone; H.R. 2471 - Consolidated Appropriations Act, 2022 - Division H - Department of Labor, Health and Human Services, and Education, and related agencies, appropriations Act, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government, substance abuse treatments and State Opioid Response Grants.

Client expense: Not reported · Firm income: $20,000

Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; H.R. 4341 and S. 987 - CARA 3.0 Act of 2021 - entire bill reauthorizing and expanding treatment and recovery for substance abuse disorders, including Medicare coverage and state programs; H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 - authorizes grants to entities for opioid response and requires prescriptions of opioid overdose reversal drugs when prescribing opioids; H.R. 4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to chemical and biological defense and access to Naloxone; H.R. 2471 - Consolidated Appropriations Act, 2022 - Division H - Department of Labor, Health and Human Services, and Education, and related agencies, appropriations Act, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government, substance abuse treatments and State Opioid Response Grants.

Client expense: Not reported · Firm income: $20,000

Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; H.R. 4341 and S. 987 - CARA 3.0 Act of 2021 - entire bill reauthorizing and expanding treatment and recovery for substance abuse disorders, including Medicare coverage and state programs; H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 - authorizes grants to entities for opioid response and requires prescriptions of opioid overdose reversal drugs when prescribing opioids; H.R. 4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to chemical and biological defense and access to Naloxone; H.R. 2471 - Consolidated Appropriations Act, 2022 - Division H - Department of Labor, Health and Human Services, and Education, and related agencies, appropriations Act, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government, substance abuse treatments and State Opioid Response Grants.

Client expense: Not reported · Firm income: $20,000

Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; H.R. 4341 and S. 987 - CARA 3.0 Act of 2021 - entire bill reauthorizing and expanding treatment and recovery for substance abuse disorders, including Medicare coverage and state programs; H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 - authorizes grants to entities for opioid response and requires prescriptions of opioid overdose reversal drugs when prescribing opioids; H.R. 4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to chemical and biological defense and access to Naloxone; H.R. 2471 - Consolidated Appropriations Act, 2022 - Division H - Department of Labor, Health and Human Services, and Education, and related agencies, appropriations Act, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government, substance abuse treatments and State Opioid Response Grants.

Client expense: Not reported · Firm income: $20,000

Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; H.R. 4341 and S. 987 - CARA 3.0 Act of 2021 - entire bill reauthorizing and expanding treatment and recovery for substance abuse disorders, including Medicare coverage and state programs; H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 - authorizes grants to entities for opioid response and requires prescriptions of opioid overdose reversal drugs when prescribing opioids; H.R. 4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to chemical and biological defense and access to Naloxone; H.R. 2471 - Consolidated Appropriations Act, 2022 - Division H - Department of Labor, Health and Human Services, and Education, and related agencies, appropriations Act, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government, substance abuse treatments and State Opioid Response Grants.

Client expense: Not reported · Firm income: $20,000

Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; H.R. 4341 and S. 987 - CARA 3.0 - entire bill reauthorizing and expanding treatment and recovery for substance abuse disorders, including Medicare coverage and state programs; H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 - authorizes grants to entities for opioid response and requires prescriptions of opioid overdose reversal drugs when prescribing opioids; H.R. 4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to chemical and biological defense and access to Naloxone; H.R. 4502 - Department of Labor, Health and Human Services, and Education, and related agencies, appropriations Act, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government, substance abuse treatments and State Opioid Response Grants.

Client expense: Not reported · Firm income: $20,000

Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; H.R. 4341 and S. 987 - CARA 3.0 - entire bill reauthorizing and expanding treatment and recovery for substance abuse disorders, including Medicare coverage and state programs; H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 - authorizes grants to entities for opioid response and requires prescriptions of opioid overdose reversal drugs when prescribing opioids; H.R. 4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to chemical and biological defense and access to Naloxone; H.R. 4502 - Department of Labor, Health and Human Services, and Education, and related agencies, appropriations Act, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government, substance abuse treatments and State Opioid Response Grants.

Client expense: Not reported · Firm income: $20,000

Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; H.R. 4341 and S. 987 - CARA 3.0 - entire bill reauthorizing and expanding treatment and recovery for substance abuse disorders, including Medicare coverage and state programs; H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 - authorizes grants to entities for opioid response and requires prescriptions of opioid overdose reversal drugs when prescribing opioids; H.R. 4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to chemical and biological defense and access to Naloxone; H.R. 4502 - Department of Labor, Health and Human Services, and Education, and related agencies, appropriations Act, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government, substance abuse treatments and State Opioid Response Grants.

Client expense: Not reported · Firm income: $20,000

Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; H.R. 4341 and S. 987 - CARA 3.0 - entire bill reauthorizing and expanding treatment and recovery for substance abuse disorders, including Medicare coverage and state programs; H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 - authorizes grants to entities for opioid response and requires prescriptions of opioid overdose reversal drugs when prescribing opioids; H.R. 4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to chemical and biological defense and access to Naloxone; H.R. 4502 - Department of Labor, Health and Human Services, and Education, and related agencies, appropriations Act, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government, substance abuse treatments and State Opioid Response Grants.

Client expense: Not reported · Firm income: $20,000

Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; H.R. 2379 - State Opioid Response Grant Authorization Program Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; Draft reauthorization of Comprehensive Addiction and Recovery Act (CARA) expanding access to treatments and recovery programs for addiction, including opioid use; S.4231 - Preparing for the Next Pandemic Act (116th Congress) - provisions for vaccines, treatment, and testing capacity, improvements to Strategic National Stockpile, and public private partnerships for public health emergencies; H.R. 4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to chemical and biological defense and access to Naloxone; H.R. 4502 - Department of Labor, Health and Human Services, and Education, and related agencies, appropriations Act, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government, substance abuse treatments and State Opioid Response Grants.

Client expense: Not reported · Firm income: $20,000

Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; H.R. 2379 - State Opioid Response Grant Authorization Program Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; Draft reauthorization of Comprehensive Addiction and Recovery Act (CARA) expanding access to treatments and recovery programs for addiction, including opioid use; S.4231 - Preparing for the Next Pandemic Act (116th Congress) - provisions for vaccines, treatment, and testing capacity, improvements to Strategic National Stockpile, and public private partnerships for public health emergencies; H.R. 4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to chemical and biological defense and access to Naloxone; H.R. 4502 - Department of Labor, Health and Human Services, and Education, and related agencies, appropriations Act, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government, substance abuse treatments and State Opioid Response Grants.

Client expense: Not reported · Firm income: $20,000

Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; H.R. 2379 - State Opioid Response Grant Authorization Program Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; Draft reauthorization of Comprehensive Addiction and Recovery Act (CARA) expanding access to treatments and recovery programs for addiction, including opioid use; S.4231 - Preparing for the Next Pandemic Act (116th Congress) - provisions for vaccines, treatment, and testing capacity, improvements to Strategic National Stockpile, and public private partnerships for public health emergencies; H.R. 4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to chemical and biological defense and access to Naloxone; H.R. 4502 - Department of Labor, Health and Human Services, and Education, and related agencies, appropriations Act, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government, substance abuse treatments and State Opioid Response Grants.

Client expense: Not reported · Firm income: $20,000

Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; H.R. 2379 - State Opioid Response Grant Authorization Program Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; Draft reauthorization of Comprehensive Addiction and Recovery Act (CARA) expanding access to treatments and recovery programs for addiction, including opioid use; S.4231 - Preparing for the Next Pandemic Act (116th Congress) - provisions for vaccines, treatment, and testing capacity, improvements to Strategic National Stockpile, and public private partnerships for public health emergencies; H.R. 4350 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to chemical and biological defense and access to Naloxone; H.R. 4502 - Department of Labor, Health and Human Services, and Education, and related agencies, appropriations Act, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government, substance abuse treatments and State Opioid Response Grants.

Client expense: Not reported · Firm income: $20,000

H.R. 2379 - State Opioid Response Grant Authorization Program Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; Draft legislation to reauthorize and expand grant programs for State responses to the opioid use disorder crisis; Draft reauthorization of Comprehensive Addiction and Recovery Act (CARA) expanding access to treatments and recovery programs for addiction, including opioid use; S.4231 - Preparing for the Next Pandemic Act (116th Congress) - provisions for vaccines, treatment, and testing capacity, improvements to Strategic National Stockpile, and public private partnerships for public health emergencies; Draft Fiscal Year 22 National Defense Authorization bill - provisions related to chemical and biological defense and access to Naloxone; Draft Department of Labor, Health and Human Services, and Education, and related agencies, appropriations bill, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government.

Client expense: Not reported · Firm income: $20,000

Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 2379 - State Opioid Response Grant Authorization Program Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; Draft legislation to reauthorize and expand grant programs for State responses to the opioid use disorder crisis; Draft reauthorization of Comprehensive Addiction and Recovery Act (CARA) expanding access to treatments and recovery programs for addiction, including opioid use; S.4231 - Preparing for the Next Pandemic Act (116th Congress) - provisions for vaccines, treatment, and testing capacity, improvements to Strategic National Stockpile, and public private partnerships for public health emergencies; Draft Fiscal Year 22 National Defense Authorization bill - provisions related to chemical and biological defense and access to Naloxone; Draft Department of Labor, Health and Human Services, and Education, and related agencies, appropriations bill, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government.

Client expense: Not reported · Firm income: $20,000

Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; H.R. 2379 - State Opioid Response Grant Authorization Program Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; Draft reauthorization of Comprehensive Addiction and Recovery Act (CARA) expanding access to treatments and recovery programs for addiction, including opioid use; S.4231 - Preparing for the Next Pandemic Act (116th Congress) - provisions for vaccines, treatment, and testing capacity, improvements to Strategic National Stockpile, and public private partnerships for public health emergencies; Draft Fiscal Year 22 National Defense Authorization bill - provisions related to chemical and biological defense and access to Naloxone; Draft Department of Labor, Health and Human Services, and Education, and related agencies, appropriations bill, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government.

Client expense: Not reported · Firm income: $20,000

Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R. 2379 - State Opioid Response Grant Authorization Program Act of 2021 - reauthorizes and expands grant programs for State responses to the opioid use disorder crisis; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; Draft legislation to reauthorize and expand grant programs for State responses to the opioid use disorder crisis; Draft reauthorization of Comprehensive Addiction and Recovery Act (CARA) expanding access to treatments and recovery programs for addiction, including opioid use; S.4231 - Preparing for the Next Pandemic Act (116th Congress) - provisions for vaccines, treatment, and testing capacity, improvements to Strategic National Stockpile, and public private partnerships for public health emergencies; Draft Fiscal Year 22 National Defense Authorization bill - provisions related to chemical and biological defense and access to Naloxone; Draft Department of Labor, Health and Human Services, and Education, and related agencies, appropriations bill, 2022 - Title II Department of Health and Human Services - funding for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government.

Client expense: Not reported · Firm income: $20,000

Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder, including S. 166/H.R. 706 - Emergency Support for Substance Use Disorders Act; Issues regarding FY22 appropriations.

Client expense: Not reported · Firm income: $60,000

H.R. 433/S.485- Family Support Services for Addiction Act H.R. 706/ S.166- Emergency Support for SUD Act H.R. 1364- Parity Enforcement Act H.R. 2352/S. 1332-Honoring National Recovery Month Act H.R. 955/S. 285 - Medicaid Reentry Act H.Res 364, Acknowledging the contributions of America's addiction professionals and their commitment to delivering evidence-based practice to individuals with substance use disorders through recognized standards of education, training, and competencies H.R. 1475- Pursuing Equity in Mental Health Act H.R. 721- Mental Health Services for Students Act H.R. 3450/S. 1727- Medicaid Bump Act H. R. 2767-Promoting Effective and Empowering Recovery Services in Medicare Act of 2021 or the PEERS Medicare Act of 2021 S. 1578/ H.R. 3150- Mental Health Professionals Workforce Shortage Loan Repayment Act of 2021 S. 1575-Improving Medicaid Programs Response to Overdose Victims and Enhancing (IMPROVE) Addiction Care Act H.R. 4244-Stopping Titles that Overtly Perpetuate (STOP) Stigma Act S. 1512/ H.R. 2903 - CONNECT for Health Act Substance Use Disorder Workforce and Infrastructure Supports Substance Use Disorder and Mental Health Parity Addiction Professional Credentials Telehealth Issues Impacting Addiction Workforce and Infrastructure Mental Health and Substance Use Nominees Child Suicide Prevention and Lethal Means Safety

Client expense: Not reported · Firm income: $30,000

H.R. 1319 - American Rescue Plan Act of 2021 - Title II, Subtitle H - provisions authorizing grants to states and community entities to address drug misuse during COVID-19, including Naloxone access; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; Draft legislation to reauthorize and expand grant programs for State responses to the opioid use disorder crisis; Draft reauthorization of Comprehensive Addiction and Recovery Act (CARA) expanding access to treatments and recovery programs for addiction, including opioid use; S.4231 - Preparing for the Next Pandemic Act (116th Congress) - provisions for vaccines, treatment, and testing capacity, improvements to Strategic National Stockpile, and public private partnerships for public health emergencies; Draft Fiscal Year 22 National Defense Authorization bill - provisions related to chemical and biological defense and access to Naloxone; Draft Fiscal Year 22 Appropriations funding for Department of Health and Human Services - proposals for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government.

Client expense: Not reported · Firm income: $20,000

H.R. 1319 - American Rescue Plan Act of 2021 - Title II, Subtitle H - provisions authorizing grants to states and community entities to address drug misuse during COVID-19, including Naloxone access; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; Draft legislation to reauthorize and expand grant programs for State responses to the opioid use disorder crisis; Draft reauthorization of Comprehensive Addiction and Recovery Act (CARA) expanding access to treatments and recovery programs for addiction, including opioid use; S.4231 - Preparing for the Next Pandemic Act (116th Congress) - provisions for vaccines, treatment, and testing capacity, improvements to Strategic National Stockpile, and public private partnerships for public health emergencies; Draft Fiscal Year 22 National Defense Authorization bill - provisions related to chemical and biological defense and access to Naloxone; Draft Fiscal Year 22 Appropriations funding for Department of Health and Human Services - proposals for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government.

Client expense: Not reported · Firm income: $20,000

H.R. 1319 - American Rescue Plan Act of 2021 - Title II, Subtitle H - provisions authorizing grants to states and community entities to address drug misuse during COVID-19, including Naloxone access; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; Draft legislation to reauthorize and expand grant programs for State responses to the opioid use disorder crisis; Draft reauthorization of Comprehensive Addiction and Recovery Act (CARA) expanding access to treatments and recovery programs for addiction, including opioid use; S.4231 - Preparing for the Next Pandemic Act (116th Congress) - provisions for vaccines, treatment, and testing capacity, improvements to Strategic National Stockpile, and public private partnerships for public health emergencies; Draft Fiscal Year 22 National Defense Authorization bill - provisions related to chemical and biological defense and access to Naloxone; Draft Fiscal Year 22 Appropriations funding for Department of Health and Human Services - proposals for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government.

Client expense: Not reported · Firm income: $20,000

H.R. 1319 - American Rescue Plan Act of 2021 - Title II, Subtitle H - provisions authorizing grants to states and community entities to address drug misuse during COVID-19, including Naloxone access; H.R. 706 and S. 166 - Emergency Support for Substance Use Disorders Act - bills authorizing grants to states and community-based entities to address substance use during COVID-19, including Naloxone distribution for opioid overdose; Draft legislation to reauthorize and expand grant programs for State responses to the opioid use disorder crisis; Draft reauthorization of Comprehensive Addiction and Recovery Act (CARA) expanding access to treatments and recovery programs for addiction, including opioid use; S.4231 - Preparing for the Next Pandemic Act (116th Congress) - provisions for vaccines, treatment, and testing capacity, improvements to Strategic National Stockpile, and public private partnerships for public health emergencies; Draft Fiscal Year 22 National Defense Authorization bill - provisions related to chemical and biological defense and access to Naloxone; Draft Fiscal Year 22 Appropriations funding for Department of Health and Human Services - proposals for development, acquisition, and stockpiling of medical countermeasures (MCM) for the U.S. Government.

Client expense: Not reported · Firm income: $20,000

Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder, including S. 166/H.R. 706 - Emergency Support for Substance Use Disorders Act; Issues regarding FY22 appropriations.

Client expense: Not reported · Firm income: $60,000

H.R. 433/S.485- Family Support Services for Addiction Act H.R. 706/ S.166- Emergency Support for SUD Act H.R. 1364- Parity Enforcement Act H.R. 434 - Preventing Mental Health and Substance Use Crises during Emergencies Act H.R. 588/S. 165 - Stopping the Mental Health Pandemic Act H.R. 708/S. 168- TREAT Act H.R. 955/S. 285 - Medicaid Reentry Act H.R.1716-Mental Health Research Act H.R. 2352-Honoring National Recovery Month Act H.R. 792- Barriers to Suicide Act Substance Use Disorder Workforce and Infrastructure Supports Substance Use Disorder and Mental Health Parity Addiction Professional Credentials

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE